retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide phase 2 trial type

Meanwhile, pharmaceutical giants Novo Nordisk and Eli Lilly have gone on the offensive, filing dozens of lawsuits in multiple states against medical spas, weight-loss clinics and pharmacies

Individual response varies some patients lose 20% on semaglutide

Tirzepatide microdosing example Strategy A: Titration with smaller increments (compounded version) Tirzepatide come in the form of prefilled pens in fixed, single-use doses (e.g., 2.5 mg, 5 mg, etc.)

The broader guide on tirzepatide and autoimmune disease provides additional context

The program is designed for individuals with a BMI of 21 or higher, representing the vast majority of US adults